Effects of β-(1,3-1,6)-d-glucan on irritable bowel syndrome-related colonic hypersensitivity

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 444-449

  Asano, Teita ^a   Tanaka, Ken ichiro ^b   Suemasu, Shintaro ^a   Ishihara, Tomoaki ^a   Tahara, Kayoko ^a   Suzuki, Toshio ^c   Suzuki, Hidekazu ^d   Fukudo, Shin ^e   Mizushima, Tohru ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Daiso Co Ltd   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glucan; Fecal pellet output; Irritable bowel syndrome; Visceral pain response

Indexed keywords

BETA (1,3 1,6) DEXTRO GLUCAN; BETA GLUCAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON DISEASE; COLON HYPERSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; INTESTINE MOTILITY; IRRITABLE COLON; MALE; MOUSE; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; VISCERAL PAIN;

ADMINISTRATION, ORAL; ANIMALS; COLON; DISEASE MODELS, ANIMAL; GLUCANS; IRRITABLE BOWEL SYNDROME; MICE; MICE, INBRED C57BL;

ANIMALIA;

EID: 84862832724     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.015     Document Type: Article

References (36)

1. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
2. Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131.
3. Shinozaki M., Fukudo S., Hongo M., Shimosegawa T., Sasaki D., Matsueda K., Harasawa S., Miura S., Mine T., Kaneko H., Arakawa T., Haruma K., Torii A., Azuma T., Miwa H., Fukunaga M., Handa M., Kitamori S., Miwa T. High prevalence of irritable bowel syndrome in medical outpatients in Japan. J. Clin. Gastroenterol. 2008, 42:1010-1016.
4. Hammerle C.W., Surawicz C.M. Updates on treatment of irritable bowel syndrome. World J. Gastroenterol. 2008, 14:2639-2649.
5. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag. Care Pharm. 2004, 10:299-309.
6. Mayer E.A., Collins S.M. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002, 122:2032-2048.
7. Okano S., Nagaya H., Ikeura Y., Natsugari H., Inatomi N. Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J. Pharmacol. Exp. Ther. 2001, 298:559-564.
8. Kobayashi S., Ikeda K., Suzuki M., Yamada T., Miyata K. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn. J. Pharmacol. 2001, 86:281-288.
9. Moriya R., Shirakura T., Hirose H., Kanno T., Suzuki J., Kanatani A. NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice. Peptides 2010, 31:671-675.
10. Munakata J., Naliboff B., Harraf F., Kodner A., Lembo T., Chang L., Silverman D.H., Mayer E.A. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997, 112:55-63.
11. Christianson J.A., Gebhart G.F. Assessment of colon sensitivity by luminal distension in mice. Nat. Protoc. 2007, 2:2624-2631.
12. Larsson M., Arvidsson S., Ekman C., Bayati A. A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists. Neurogastroenterol. Motil. 2003, 15:371-381.
13. Treem W.R., Ahsan N., Kastoff G., Hyams J.S. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J. Pediatr. Gastroenterol. Nutr. 1996, 23:280-286.
14. C. Tana, Y. Umesaki, A. Imaoka, T. Handa, M. Kanazawa, S. Fukudo, Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome, Neurogastroenterol. Motil. 22 (2010) 512-519, e114-515.
15. Bourdu S., Dapoigny M., Chapuy E., Artigue F., Vasson M.P., Dechelotte P., Bommelaer G., Eschalier A., Ardid D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005, 128:1996-2008.
16. Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., Ouwehand A., Leyer G., Carcano D., Colombel J.F., Ardid D., Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 2007, 13:35-37.
17. Chen J., Seviour R. Medicinal importance of fungal beta-(1→3), (1→6)-glucans. Mycol. Res. 2007, 111:635-652.
18. Tsoni S.V., Brown G.D. Beta-Glucans and dectin-1. Ann. NY Acad. Sci. 2008, 1143:45-60.
19. Berdal M., Appelbom H.I., Eikrem J.H., Lund A., Zykova S., Busund L.T., Seljelid R., Jenssen T. Aminated beta-1,3-d-glucan improves wound healing in diabetic db/db mice. Wound Repair Regen. 2007, 15:825-832.
20. Bell S., Goldman V.M., Bistrian B.R., Arnold A.H., Ostroff G., Forse R.A. Effect of beta-glucan from oats and yeast on serum lipids. Crit. Rev. Food Sci. Nutr. 1999, 39:189-202.
21. Sener G., Eksioglu-Demiralp E., Cetiner M., Ercan F., Yegen B.C. Beta-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects. Eur. J. Pharmacol. 2006, 542:170-178.
22. Bedirli A., Kerem M., Pasaoglu H., Akyurek N., Tezcaner T., Elbeg S., Memis L., Sakrak O. Beta-glucan attenuates inflammatory cytokine release and prevents acute lung injury in an experimental model of sepsis. Shock 2007, 27:397-401.
23. Lyuksutova O.I., Murphey E.D., Toliver-Kinsky T.E., Lin C.Y., Cui W., Williams D.L., Sherwood E.R. Glucan phosphate treatment attenuates burn-induced inflammation and improves resistance to Pseudomonas aeruginosa burn wound infection. Shock 2005, 23:224-232.
24. Soltys J., Quinn M.T. Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan. Infect. Immun. 1999, 67:244-252.
25. Toklu H.Z., Sehirli A.O., Velioglu-Ogunc A., Cetinel S., Sener G. Acetaminophen-induced toxicity is prevented by beta-d-glucan treatment in mice. Eur. J. Pharmacol. 2006, 543:133-140.
26. Shah V.B., Williams D.L., Keshvara L. Beta-glucan attenuates TLR2- and TLR4-mediated cytokine production by microglia. Neurosci. Lett. 2009, 458:111-115.
27. Kimura Y., Sumiyoshi M., Suzuki T., Sakanaka M. Effects of water-soluble low-molecular-weight beta-1, 3-d-glucan (branch beta-1, 6) isolated from Aureobasidium pullulans 1A1 strain black yeast on restraint stress in mice. J. Pharm. Pharmacol. 2007, 59:1137-1144.
28. Kimura Y., Sumiyoshi M., Suzuki T., Sakanaka M. Antitumor and antimetastatic activity of a novel water-soluble low molecular weight beta-1, 3-d-glucan (branch beta-1,6) isolated from Aureobasidium pullulans 1A1 strain black yeast. Anticancer Res. 2006, 26:4131-4141.
29. Kimura Y., Sumiyoshi M., Suzuki T., Sakanaka M. Inhibitory effects of water-soluble low-molecular-weight beta-(1,3-1,6) d-glucan purified from Aureobasidium pullulans GM-NH-1A1 strain on food allergic reactions in mice. Int Immunopharmacol 2007, 7:963-972.
30. Tanaka K., Tanaka Y., Suzuki T., Mizushima T. Protective effect of beta-(1,3 → 1,6)-d-glucan against irritant-induced gastric lesions. Br. J. Nutr. 2011, 106:475-485.
31. Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., Lee K.F. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J. Neurosci. 2002, 22:193-199.
32. Ravnefjord A., Brusberg M., Larsson H., Lindstrom E., Martinez V. Effects of pregabalin on visceral pain responses and colonic compliance in rats. Br. J. Pharmacol. 2008, 155:407-416.
33. Saito-Nakaya K., Hasegawa R., Nagura Y., Ito H., Fukudo S. Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogastroenterol. Motil. 2008, 20:1147-1156.
34. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 1957, 111:409-419.
35. Mazzon E., Cuzzocrea S. Role of TNF-alpha in ileum tight junction alteration in mouse model of restraint stress. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G1268-G1280.
36. Saito T., Mizutani F., Iwanaga Y., Morikawa K., Kato H. Laxative and anti-diarrheal activity of polycarbophil in mice and rats. Jpn. J. Pharmacol. 2002, 89:133-141.